Sutro Biopharma, Inc.
STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer targetā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.82
Price-13.36%
-$0.12
1Y
Price
Market Cap
$69.201m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-5.2%
EBITDA Margin-18.0%
Net Profit Margin-70.3%
Free Cash Flow MarginRevenue
$104.473m
+68.4%
1y CAGR+45.2%
3y CAGR+36.3%
5y CAGREarnings
-$208.697m
+8.3%
1y CAGR-31.4%
3y CAGR-26.8%
5y CAGREPS
-$2.52
+14.9%
1y CAGR-9.1%
3y CAGR-7.4%
5y CAGRBook Value
-$32.111m
$262.355m
Assets$294.466m
Liabilities$19.593m
DebtDebt to Assets
7.5%
-0.1x
Debt to EBITDAFree Cash Flow
-$252.017m
-29.5%
1y CAGR-895.9%
3y CAGR-648.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company